Precipio Announces Q4 and Year-End 2025 Shareholder Update Call

Precipio, Inc. ($PRPO), a specialty cancer diagnostics company, is hosting a shareholder update call on April 2, 2026, to discuss fourth-quarter and full-year 2025 financial results and operational highlights. The announcement comes as the company reports robust revenue growth and strengthens its clinical validation through a high-profile research partnership, signaling momentum in an increasingly competitive precision diagnostics market.

The NASDAQ-listed diagnostics firm delivered preliminary unaudited revenues of $24.0 million for 2025, marking a 30% year-over-year increase from the prior year. This acceleration reflects growing adoption of its specialty cancer testing portfolio amid expanding demand for blood-based biomarker diagnostics and personalized oncology solutions. Alongside the financial announcement, Precipio published a significant joint study with Memorial Sloan-Kettering Cancer Center on its proprietary Bloodhound BCR::ABL1 assay in the Journal of Clinical Pathology, adding peer-reviewed validation to one of its flagship diagnostic offerings.

Key Details: Revenue Growth and Clinical Validation

The $24.0 million in preliminary 2025 revenues represents meaningful scale-up for the specialty diagnostics player, with the 30% growth rate outpacing general market trends in molecular diagnostics. This performance comes as Precipio continues to expand its testing capabilities and market reach in the oncology diagnostics space, where precision medicine increasingly drives clinical decision-making and patient outcomes.

The joint publication with Memorial Sloan-Kettering Cancer Center—one of the nation's premier cancer research institutions—represents a significant validation milestone. The study focused on Precipio's Bloodhound BCR::ABL1 assay, a blood-based test designed to detect and monitor BCR::ABL1 fusion genes, which are critical biomarkers in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Publication in a peer-reviewed journal like Clinical Pathology enhances clinical credibility, potentially supporting reimbursement discussions with payers and adoption among oncologists and hematologists.

Key metrics from the announcement include:

• $24.0 million preliminary unaudited revenues for full-year 2025
• 30% year-over-year growth rate
• Peer-reviewed publication in major clinical pathology journal
• Partnership validation from Memorial Sloan-Kettering Cancer Center
• Scheduled Q4 and full-year earnings call for April 2, 2026

Market Context: Precision Diagnostics in High Demand

The oncology diagnostics market continues expanding rapidly, driven by several converging trends: rising cancer incidence rates, increasing adoption of molecular testing in treatment protocols, shift toward early detection through blood-based biomarkers, and growing personalized medicine adoption among healthcare systems. Precipio's revenue acceleration reflects these secular tailwinds, though the company operates in a crowded landscape facing competition from larger diagnostic incumbents and well-funded liquid biopsy startups.

The blood-based cancer testing segment specifically has become a battleground for innovation and market share. Companies across the spectrum—from established players like Quest Diagnostics and LabCorp to specialized firms and newer liquid biopsy entrants—are racing to develop and commercialize circulating tumor DNA (ctDNA) tests, minimal residual disease (MRD) assays, and other blood biomarkers. Precipio's focus on BCR::ABL1 and its cancer diagnostics portfolio positions it in this high-growth category, where reimbursement rates have generally improved and clinical adoption continues accelerating.

The Memorial Sloan-Kettering publication particularly matters because academic medical centers drive clinical practice standards and treatment protocols. When leading cancer institutions validate diagnostic tools through published research, it legitimizes those tools for broader adoption across community hospitals, oncology practices, and laboratory networks. This type of clinical validation often precedes reimbursement improvements and wider market penetration.

Regulatory environment in precision diagnostics remains evolving. While FDA oversight of laboratory-developed tests (LDTs) has been a topic of ongoing discussion, current pathways allow validated tests to enter clinical practice. Publication in established medical journals bolsters the regulatory and clinical standing of diagnostic assays, potentially supporting future label claims or coverage determinations by major payers.

Investor Implications: Growth Trajectory and Validation Signals

For $PRPO shareholders, the 30% revenue growth signals successful commercialization of the company's diagnostic offerings and expanding market share in an attractive segment. Achieving this growth rate in specialty diagnostics—particularly for a smaller, NASDAQ-listed player—demonstrates execution capability and market demand.

The Memorial Sloan-Kettering partnership and peer-reviewed publication represent tangible clinical validation that transcends marketing claims. For diagnostic companies, clinical proof-of-concept published in credible journals directly impacts:

• Reimbursement discussions with major health insurers and Medicare
• Provider adoption among oncologists and laboratory networks
• Market expansion into new healthcare systems and geographies
• Competitive positioning against rival diagnostic platforms
• Stock narrative with investors seeking growth in validated technology platforms

The April 2 shareholder call will provide full-year audited results, margin analysis, guidance for 2026, and potentially color on customer acquisition costs, test volume trends, and reimbursement status. Investors will be watching for:

• Gross margins on the $24.0M revenue base and trajectory
• Reimbursement mix across public and private payers
• Test volume metrics and average revenue per test
• Geographic expansion plans and market penetration rates
• Pipeline updates on new assays and clinical validation efforts
• 2026 guidance and longer-term growth expectations

For a specialty diagnostics company, sustained high-single-digit or double-digit revenue growth combined with clinical validation creates a compelling investment narrative—particularly if margins are expanding and reimbursement is improving. The Memorial Sloan-Kettering publication strengthens that narrative substantially.

Looking Ahead

Precipio Inc. enters its April 2 shareholder update from a position of momentum, having achieved 30% revenue growth while securing peer-reviewed validation from a world-class cancer research institution. The combination of financial acceleration and clinical credibility addresses two critical investor concerns: market demand and technical legitimacy. As precision oncology diagnostics continue reshaping cancer care, Precipio's ability to scale its test offerings and expand reimbursement coverage will determine whether this growth trajectory proves sustainable. The company's Q4 and full-year 2025 results, along with management commentary on 2026 opportunities, will clarify whether $PRPO is positioned as a durable consolidator in specialty cancer diagnostics or faces intensifying competitive pressures. Investors should focus on margin sustainability, customer concentration, and reimbursement trends as key barometers of long-term value creation.